General contact

Main switchboard

+41 61 324 11 11
+41 61 324 80 01
Monday - Friday,
8:30 a.m. - 5:00 p.m. GMT+1

US switchboard

+1 862 778 21 00
Monday - Friday,
8:30 a.m. - 5:00 p.m. EST


Global Media Relations
Eric Althoff
Basel, Switzerland

+41 61 324 7999


Investor Relations

Monday - Friday,
8:30 a.m. - 5:30 p.m. GMT+1
(Central European Time)

Reporting side effects

Report a suspected side effect (also known as an adverse event) related to a Novartis Pharmaceutical drug or a Novartis Vaccine.

Reporting side effects

pane 4 content

Clinical trial information disclosure

Research based companies are required to prove the safety and efficacy of all new medicines in clinical trials. Clinical studies in humans must comply with ethical principles, as agreed in the Declaration of Helsinki, which protects the safety and well-being of study participants. All Novartis clinical studies are therefore designed and conducted in accordance with the ethical principles of the Declaration of Helsinki, Good Clinical Practice guidelines as well as other national and international regulatory requirements.

Clinical trial information disclosure at Novartis

Providing access to information about clinical research studies and their results benefits study participants, patients, healthcare providers and the wider public. This information helps people make informed decisions about potential treatment options as well as potential participation in clinical studies. Novartis discloses the design and results of all interventional clinical studies for innovative treatments in patients regardless of the outcome. We make the results of our clinical trials publicly available through peer-reviewed publications and by posting the results on the Novartis clinical trial results website as well as other online public databases.

To learn more about how Novartis is leading in clinical trial data transparency:

To learn more about the results of Novartis-conducted trials, visit:

Sharing patient-level data: Novartis is also committed to providing access to patient-level data and clinical study reports from eligible studies to qualified external researchers. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trials in line with applicable laws and regulations.

In 2014, Novartis began to make patient-level data available for medicines and vaccines that received a regulatory approval in 2014 for a specified indication in both the EU and U.S. For more detailed information about patient-level data eligibility criteria and for external access requests please visit: